News Feed Opinion Blog Posts Career Updates Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
September, 2025
September 2025
M T W T F S S
1234567
891011121314
15161718192021
22232425262728
2930  
Vivek Subbiah: How Aggressive Brain Tumors Exploit Glucose to Suppress Normal Activity
Vivek Subbiah/LinkedIn
Sep 5, 2025, 09:41

Vivek Subbiah: How Aggressive Brain Tumors Exploit Glucose to Suppress Normal Activity

Vivek Subbiah, Chief, Early-Phase Drug Development at Sarah Cannon Research Institute, shared on LinkedIn:

“Interesting paper published in Nature shows.

How aggressive brain tumours exploit glucose to suppress normal physiological activity in favour of malignant expansion and offer potential therapeutic strategies to enhance treatment outcomes.”

Title: Rewiring of cortical glucose metabolism fuels human brain cancer growth

Authors: Andrew J. Scott, Anjali Mittal, Baharan Meghdadi, Alexandra O’Brien, Justine Bailleul, Palavalasa Sravya, Abhinav Achreja, Weihua Zhou, Jie Xu, Angelica Lin, Kari Wilder-Romans, Ningning Liang, Ayesha U. Kothari, Navyateja Korimerla, Donna M. Edwards, Zhe Wu, Jiane Feng, Sophia Su, Li Zhang, Peter Sajjakulnukit, Anthony C. Andren, Junyoung O. Park, Johanna ten Hoeve, Vijay Tarnal, Daniel R. Wahl

Read The Full Article at Nature.

Vivek Subbiah: How Aggressive Brain Tumors Exploit Glucose to Suppress Normal Activity

See more articles about Vivek Subbiah.

Abhinav Achreja Alexandra O’Brien Andrew J. Scott Angelica Lin Anjali Mittal Anthony C. Andren Ayesha U. Kothari Baharan Meghdadi cancer Daniel R. Wahl Donna M. Edwards Jiane Feng Jie Xu Johanna ten Hoeve Junyoung O. Park Justine Bailleul Kari Wilder-Romans Li Zhang Nature Navyateja Korimerla Ningning Liang OncoDaily Oncology Palavalasa Sravya Peter Sajjakulnukit Sophia Su Vijay Tarnal Vivek Subbiah Weihua Zhou Zhe Wu
Special Coverage
Science
Sep 5, 2025, 09:41
Vivek Subbiah: How Aggressive Brain Tumors Exploit Glucose to Suppress Normal Activity
Voices
Sep 5, 2025, 08:57
Honoring a Life of Compassion and Impact - CancerWorld
Voices
Sep 5, 2025, 08:57
C/Can Advances Breast Imaging Training for Global Cities
FDA Approvals
Sep 5, 2025, 08:44
Olomorasib Receives FDA Breakthrough Therapy Designation for KRAS G12C-Mutant NSCLC
Voices
Sep 5, 2025, 08:36
Miriam Mutebi: Scalpel-Wielding Surgeon is Terrified of Needles - Especially When They’re Aimed at Me
Dialogues
Sep 5, 2025, 08:09
ONCOFFEE: Gabriela Inés Villanueva – From Argentina to the US and Back, Shaping Pediatric Oncology
Dialogues
Sep 5, 2025, 08:07
Roche’s CMO Levi Garraway on Personal Journey, Developing Foundation Medicine, and Cancer Research
Dialogues
Sep 5, 2025, 08:05
What Happens When Cancer Meets a Global Pandemic? | Patient stories
Dialogues
Sep 5, 2025, 08:05
How Will Supportive Care for Cancer Survivors Evolve by 2030? | MASCC 2025
Dialogues
Sep 5, 2025, 08:04
Empowering Oncologists: How do I successfully own an oncology practice?
Voices
Sep 5, 2025, 07:48
Rasha Aboelhassan: Patients are Struggling, But There is Hope in Near Future
Voices
Sep 5, 2025, 07:15
Vun-Sin Lim: Interferon Epsilon Loss and Immune-Cold Tumors